Magnesium for sleep and stress: what to expect
What magnesium studies found for sleep and stress, which forms were studied, and what to consider for safety.
Key points
- In healthy adults with poor sleep, a magnesium bisglycinate and glycine complex produced a small additional reduction in insomnia severity over four weeks compared with placebo. The result remained uncertain, so any possible improvement in sleep may be small. [1] See the evidence 1
- The same study found no convincing difference in sleep quality or daytime sleepiness. No additional improvement over placebo was detected for these measures. [1] See the evidence 1 2
- Studies of healthy adults with poor sleep and people with fibromyalgia found no convincing overall reduction in stress measures; in the first group no difference in anxiety scores was found either. No convincing overall effect was detected in these groups over four weeks. [1] [2] See the evidence 1 2 3
Practical guide
Check the conclusions and whether they apply to your situation.
Magnesium has been studied for poor sleep and stress. Results differ by measure and apply to specific groups and formulations.
What to expect
Why these conclusions
Sleep and stress results
In a study of healthy adults aged 18–65 with poor sleep, the complex provided 250 mg elemental magnesium and 1,523 mg glycine daily for 28 days. Insomnia severity fell by an additional 1.6 points versus placebo, but the rounded interval includes no difference; glycine’s contribution was not studied separately. [1]
No convincing additional difference in sleep quality or daytime sleepiness was found in the same study. [1]
In healthy adults with poor sleep, the same complex showed no convincing difference in stress or anxiety scores. In people with fibromyalgia and stress, magnesium chloride providing 100 mg elemental magnesium daily for 28 days also showed no convincing overall advantage on the stress measure. [1] [2]
ISI fell by an additional 1.6 points; the rounded confidence interval includes no difference. Glycine’s effect was not studied separately.
| Parameter | Data |
|---|---|
| Result | ISI fell by an additional 1.6 points; the rounded confidence interval includes no difference. Glycine’s effect was not studied separately. |
| Participants | 155 randomised healthy adults aged 18–65 with poor sleep; 153 were included in the primary analysis |
| Form | Magnesium bisglycinate and glycine complex |
| Dose | 250 mg elemental magnesium and 1,523 mg glycine daily, two capsules |
| Dose basis | 250 mg elemental magnesium and 1,523 mg glycine daily, two capsules |
| Comparator | placebo or control under comparable conditions |
| Duration | 28 days |
| Confidence | 2/4: Risk of bias: Attrition, incomplete original plans or limited assessment of individual trials’ risk.; Consistency: No serious unexplained heterogeneity was found for the specific outcome. There is no additional reduction in confidence on this basis.; Applicability to the specified group: The conclusion is limited to the specified group, dose and outcome. There is no additional reduction in confidence on this basis.; Precision: A small sample and a wide or unreported interval leave substantial uncertainty.; Possible publication bias: No specific reason for a separate reduction; unpublished data cannot be ruled out. There is no additional reduction in confidence on this basis. |
| Evidence base | 1 publication described |
| Sources | [1] |
No convincing additional difference in SQS was found; a small effect cannot be ruled out.
| Parameter | Data |
|---|---|
| Result | No convincing additional difference in SQS was found; a small effect cannot be ruled out. |
| Participants | Healthy adults aged 18–65 with poor sleep |
| Form | Magnesium bisglycinate and glycine complex |
| Dose | 250 mg elemental magnesium and 1,523 mg glycine daily, two capsules |
| Dose basis | 250 mg elemental magnesium and 1,523 mg glycine daily, two capsules |
| Comparator | Placebo |
| Duration | 28 days |
| Confidence | 2/4: Risk of bias: Attrition, incomplete original plans or limited assessment of individual trials’ risk.; Consistency: No serious unexplained heterogeneity was found for the specific outcome. There is no additional reduction in confidence on this basis.; Applicability to the specified group: The conclusion is limited to the specified group, dose and outcome. There is no additional reduction in confidence on this basis.; Precision: A small sample and a wide or unreported interval leave substantial uncertainty.; Possible publication bias: No specific reason for a separate reduction; unpublished data cannot be ruled out. There is no additional reduction in confidence on this basis. |
| Evidence base | 1 publication described |
| Sources | [1] |
No convincing difference in daytime sleepiness was found.
| Parameter | Data |
|---|---|
| Result | No convincing difference in daytime sleepiness was found. |
| Participants | Healthy adults aged 18–65 with poor sleep |
| Form | Magnesium bisglycinate and glycine complex |
| Dose | 250 mg elemental magnesium and 1,523 mg glycine daily, two capsules |
| Dose basis | 250 mg elemental magnesium and 1,523 mg glycine daily, two capsules |
| Comparator | Placebo |
| Duration | 28 days |
| Confidence | 2/4: Risk of bias: Attrition, incomplete original plans or limited assessment of individual trials’ risk.; Consistency: No serious unexplained heterogeneity was found for the specific outcome. There is no additional reduction in confidence on this basis.; Applicability to the specified group: The conclusion is limited to the specified group, dose and outcome. There is no additional reduction in confidence on this basis.; Precision: A small sample and a wide or unreported interval leave substantial uncertainty.; Possible publication bias: No specific reason for a separate reduction; unpublished data cannot be ruled out. There is no additional reduction in confidence on this basis. |
| Evidence base | 1 publication described |
| Sources | [1] |
The PSS comparison showed no convincing difference; participants were not selected for stress.
| Parameter | Data |
|---|---|
| Result | The PSS comparison showed no convincing difference; participants were not selected for stress. |
| Participants | Healthy adults with poor sleep |
| Form | Magnesium bisglycinate and glycine complex |
| Dose | 250 mg elemental magnesium and 1,523 mg glycine daily, two capsules |
| Dose basis | 250 mg elemental magnesium and 1,523 mg glycine daily, two capsules |
| Comparator | placebo or control under comparable conditions |
| Duration | 28 days |
| Confidence | 2/4: Risk of bias: Attrition, incomplete original plans or limited assessment of individual trials’ risk.; Consistency: No serious unexplained heterogeneity was found for the specific outcome. There is no additional reduction in confidence on this basis.; Applicability to the specified group: The question specifically concerns people with poor sleep and PSS stress or PHQ anxiety scores. It does not imply a general conclusion about treating anxiety. There is no additional reduction in confidence on this basis.; Precision: A small sample and a wide or unreported interval leave substantial uncertainty.; Possible publication bias: No specific reason for a separate reduction; unpublished data cannot be ruled out. There is no additional reduction in confidence on this basis. |
| Evidence base | 1 publication described |
| Sources | [1] |
No difference was found on the PHQ-4 anxiety subscale; small effects cannot be ruled out.
| Parameter | Data |
|---|---|
| Result | No difference was found on the PHQ-4 anxiety subscale; small effects cannot be ruled out. |
| Participants | Healthy adults with poor sleep |
| Form | Magnesium bisglycinate and glycine complex |
| Dose | 250 mg elemental magnesium and 1,523 mg glycine daily, two capsules |
| Dose basis | 250 mg elemental magnesium and 1,523 mg glycine daily, two capsules |
| Comparator | placebo or control under comparable conditions |
| Duration | 28 days |
| Confidence | 2/4: Risk of bias: Attrition, incomplete original plans or limited assessment of individual trials’ risk.; Consistency: No serious unexplained heterogeneity was found for the specific outcome. There is no additional reduction in confidence on this basis.; Applicability to the specified group: The question specifically concerns people with poor sleep and PSS stress or PHQ anxiety scores. It does not imply a general conclusion about treating anxiety. There is no additional reduction in confidence on this basis.; Precision: A small sample and a wide or unreported interval leave substantial uncertainty.; Possible publication bias: No specific reason for a separate reduction; unpublished data cannot be ruled out. There is no additional reduction in confidence on this basis. |
| Evidence base | 1 publication described |
| Sources | [1] |
Mean score on day 28 was 21.8 versus 21.6; no convincing overall advantage was found.
| Parameter | Data |
|---|---|
| Result | Mean score on day 28 was 21.8 versus 21.6; no convincing overall advantage was found. |
| Participants | Patients with fibromyalgia and stress |
| Form | magnesium chloride |
| Dose | 100 mg elemental Mg/day |
| Dose basis | 100 mg elemental Mg/day |
| Comparator | placebo or control under comparable conditions |
| Duration | 28 days |
| Confidence | 2/4: Risk of bias: Attrition, incomplete original plans or limited assessment of individual trials’ risk.; Consistency: No serious unexplained heterogeneity was found for the specific outcome. There is no additional reduction in confidence on this basis.; Applicability to the specified group: The conclusion is limited to the specified group, dose and outcome. There is no additional reduction in confidence on this basis.; Precision: A small sample and a wide or unreported interval leave substantial uncertainty.; Possible publication bias: No specific reason for a separate reduction; unpublished data cannot be ruled out. There is no additional reduction in confidence on this basis. |
| Evidence base | 1 publication described |
| Sources | [2] |
High doses of magnesium from supplements or medicines often cause diarrhoea, sometimes with nausea and abdominal cramps; toxicity risk is higher with impaired kidney function.
| Parameter | Data |
|---|---|
| Result | High doses of magnesium from supplements or medicines often cause diarrhoea, sometimes with nausea and abdominal cramps; toxicity risk is higher with impaired kidney function. |
| Participants | General information; especially with reduced kidney function |
| Form | Not applicable: the statement concerns magnesium or the category as a whole; the source does not specify a particular form. |
| Dose | The source does not specify a universally safe dose for an individual |
| Dose basis | The source does not specify a universally safe dose for an individual |
| Comparator | Not applicable: descriptive fact, without a comparative study. |
| Duration | Not applicable: descriptive fact; intervention duration is not assessed. |
| Confidence | A numerical effectiveness rating does not apply to this reference entry. |
| Evidence base | Named publications: 1 |
| Sources | [3] |
NIH states a tolerable upper level of 350 mg magnesium daily from supplements and medicines for adults; this is a limit for the healthy population, not a target dose.
| Parameter | Data |
|---|---|
| Result | NIH states a tolerable upper level of 350 mg magnesium daily from supplements and medicines for adults; this is a limit for the healthy population, not a target dose. |
| Participants | Healthy adults |
| Form | Not applicable: the statement concerns magnesium or the category as a whole; the source does not specify a particular form. |
| Dose | 350 mg/day elemental magnesium from supplements and medicines |
| Dose basis | 350 mg/day elemental magnesium from supplements and medicines |
| Comparator | Not applicable: descriptive fact, without a comparative study. |
| Duration | Not applicable: descriptive fact; intervention duration is not assessed. |
| Confidence | A numerical effectiveness rating does not apply to this reference entry. |
| Evidence base | Named publications: 1 |
| Sources | [3] |
More details
Amount and safety
High doses of magnesium from supplements or medicines can cause diarrhoea, nausea and abdominal cramps; toxicity risk is higher with reduced kidney function. If the expected change in sleep does not occur, do not automatically increase the dose; discuss continuing problems with a professional. [3]
In the US, the tolerable upper intake level for healthy adults is 350 mg elemental magnesium daily from supplements and medicines. This is a limit, not a recommended target dose. [3]
Sources
- Magnesium Bisglycinate Supplementation in Healthy Adults Reporting Poor Sleep: A Randomized, Placebo-Controlled Trial. https://pubmed.ncbi.nlm.nih.gov/40918053/
- Short-Term Magnesium Therapy Alleviates Moderate Stress in Patients with Fibromyalgia: A Randomized Double-Blind Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/35631229/
- Magnesium: Fact Sheet for Health Professionals. https://ods.od.nih.gov/factsheets/Magnesium-HealthProfessional/
Methodology: Subpages evidence-led supplement pipeline v1